Panacea Biotec Limited up by 9.99%: Traders Market Update| Espresso


Espresso shot of the day – Panacea Biotec Ltd up by 9.99 percent

August 04, 2021
Espresso shot of the day – Panacea Biotec Ltd up by 9.99 percent

PANACEA BIOTEC LTD 346.80 (+ 9.99%) BSE – INE922B01023 | 4TH AUGUST 2021

Panacea Biotec is an innovation-driven biotechnology company engaged in Research and Development, Manufacturing, Sales, Distribution and Marketing of Pharmaceuticals, Vaccines and Biosimilars. Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private Limited with a commitment to make innovative products affordable and accessible to the masses. Panacea Biotec is witnessing a period of expansion across every aspect of business, from innovative products to customers in markets, from manufacturing to regulatory approvals, and thereby laying the foundation for translation of their vision to become the greatest, largest and most admired biotechnology company in the world.

Recent Drivers

  • On Aug 1, 2021, the Russian Direct Investment Fund (RDIF) informed the production of Russia's coronavirus vaccine Sputnik V in India is expected to come fully on stream in September. A statement issued by RDIF read, "Production in India is expected to come fully on stream in September and RDIF expects India to become a major production hub for the Sputnik V vaccine with such companies as Serum Institute of India (the world's biggest vaccine producer), Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech and Morepen Laboratories working to produce the vaccine."
  • On July 27, 2021, Panacea Biotec reported net sales at Rs 36.26 crores in June 2021.
  • On July 20, 2021, the Central Drugs Standard Control Organisation (CDSCO) has granted manufacturing permission to private manufacturers for three coronavirus vaccines for restricted use in emergency situation. These vaccines are ChAdOx1 nCoV-19 corona virus vaccine (recombinant) manufactured by the Serum Institute of India (SII); whole virion-inactivated corona virus vaccine manufactured by Bharat Biotech International Limited; and Gam-COVID-Vac combined vector vaccine (Sputnik-V) manufactured by Ra (biologicals) Panacea Biotec, New Delhi.
  • On July 4, 2021, Panacea Biotec announced it has received manufacturing licence from Drugs Controller General India for COVID-19 vaccine Sputnik V.
  • On June 2, 2021, the Board of Panacea Biotec at its meeting approved the raising of funds up to Rs 1,200 crores by way of issuance of equity shares and/or other securities, including share warrants, bonds, foreign currency convertible bonds, debentures and/or any other equity-based instruments/securities including through qualified institutions placement, preferential issue, private placement, rights issue, or through any other permissible mode or any combination thereof in the domestic and/or international markets and/or by way of raising debt funds including ECB, as may be permitted under applicable laws, in one or more tranches.
(Sources: Moneycontrol, Business Standard, ETHealthWorld, Express Pharma, The Hindu Business Line)

Technical Force*

  • S&P BSE Small Cap month till date gain up by 0.23%
  • Touched upper circuit of Rs 346.80
  • Spurt in volume by more than 3.16 times compare to previous volume | 3 months avg. volume: 1,32,434
  • Quantity traded: 1,28,969 | Deliverable quantity: 72,842 (56.48%)
  • Stock price has jumped more than 100% from one-year low level: 171.00 (Nov 2, 2020)
  • Daily RSI (14) is in OverSold territory today
  • 52-week-high: 453.70 | 52-week-low: 171.00

Key Pivot  (Yearly)










Pivot Point










Fibonacci Pivot










Today’s Close




10 DAY


20 DAY


50 DAY


200 DAY


Some Key Ratios (Source: BSE)

Market Cap: 2,124.18 crores

PE: -73.07

OPM%: -42.08

ROE%: -5.72

Promoters holding%: 73.59

Prev. Close: 315.30

*Chart And Technical Force data taken from the Binge desktop app.

The scope and usability of this information/data is time-sensitive and market-based, and as such the same may become outdated for the investment decisions of clients, for which Sharekhan comtrade bears no responsibility. References to securities do not constitute a recommendation to buy, sell or hold such securities. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document and should consult his own advisors to determine the merits and risks of such an investment. Sharekhan Comtrade Private Limited is under no obligation to update the information in this document from time-to-time.

Chandresh Khona
by Chandresh Khona

Product Offerings Head

A teacher, writer, travel buff and now Espresso's Product Offerings Head. Ten years here has allowed me to lead the digital team at Sharekhan. My true passion lies in stock market charts.